These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 27449228)

  • 1. Physiologically Based Pharmacokinetic Modeling for Substitutability Analysis of Venlafaxine Hydrochloride Extended-Release Formulations Using Different Release Mechanisms: Osmotic Pump Versus Openable Matrix.
    Lin HP; Sun D; Zhang X; Wen H
    J Pharm Sci; 2016 Oct; 105(10):3088-3096. PubMed ID: 27449228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Bioavailability of Single-Dose Extended-Release Venlafaxine Capsules in Obese Patients Before and After Gastric Bypass Surgery.
    Krieger CA; Cunningham JL; Reid JM; Langman LJ; Grothe KB; Clark MM; Dierkhising RA
    Pharmacotherapy; 2017 Nov; 37(11):1374-1382. PubMed ID: 28845898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioequivalence of single and multiple doses of venlafaxine extended-release tablets and capsules in the fasted and fed states: four open-label, randomized crossover trials in healthy volunteers.
    Wright CW; Aikman MS; Werts E; Seabolt J; Haeusler JM
    Clin Ther; 2009 Nov; 31(11):2722-34. PubMed ID: 20110014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined site-specific release retardant mini-matrix tablets (C-SSRRMT) for extended oral delivery of dexketoprofen trometamol:
    Sweed NM; Basalious EB; Nour SA
    Drug Dev Ind Pharm; 2019 Nov; 45(11):1777-1787. PubMed ID: 31418598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of a single and chronic administration of venlafaxine on tramadol pharmacokinetics in a rabbit model.
    Szkutnik-Fiedler D; Grabowski T; Balcerkiewicz M; Michalak M; Pilipczuk I; Wyrowski Ł; Urjasz H; Grześkowiak E
    Pharmacol Rep; 2017 Jun; 69(3):555-559. PubMed ID: 28364695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects.
    Teng R; Kujacic M; Hsia J
    Clin Ther; 2014 Sep; 36(9):1217-25. PubMed ID: 25069798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and uniform evaluation of ropinirole osmotic pump tablets with REQUIP XL both in vitro and in beagle dogs.
    Li Z; Yu F; Di Z; Zhao X; Zhao S; Liu Y; Li Y; Wang Z; Gong W; Zhang H; Yang Y; Xie X; Mei X
    Drug Dev Ind Pharm; 2016 Jan; 42(1):12-18. PubMed ID: 25830369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Change in formulation and its potential clinical and pharmacoeconomic value: example of extended release venlafaxine.
    Haeusler JM
    Curr Med Res Opin; 2009 May; 25(5):1089-94. PubMed ID: 19301988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vitro-In Vivo Correlation for Desvenlafaxine Succinate Monohydrate Extended Release Tablets.
    da Silva JD; de Sousa VP; Cabral LM; Davanço MG; Meulman J; de Oliveira Carvalho P; Campos DR
    AAPS PharmSciTech; 2020 Jul; 21(5):195. PubMed ID: 32666354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucoadhesive elementary osmotic pump tablets of trimetazidine for controlled drug delivery and reduced variability in oral bioavailability.
    Alam N; Beg S; Rizwan M; Ahmad A; Ahmad FJ; Ali A; Aqil M
    Drug Dev Ind Pharm; 2015 Apr; 41(4):692-702. PubMed ID: 24669975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative in vitro and in vivo evaluation of matrix, osmotic matrix, and osmotic pump tablets for controlled delivery of diclofenac sodium.
    Rani M; Mishra B
    AAPS PharmSciTech; 2004 Aug; 5(4):e71. PubMed ID: 15760068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Optimization of a floating osmotic pump system of ambroxol hydrochloride using central composite design-response surface methodology and its pharmacokinetics in Beagle dogs].
    Zhao F; Ma YL; Jin XL; Wang J; Cao DY
    Yao Xue Xue Bao; 2011 Dec; 46(12):1507-14. PubMed ID: 22375427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioequivalence of oxycodone hydrochoride extended release tablets to marketed reference products OxyContin® in Canada and US.
    Gosai P; Ducharme MP; Godfrey AR; Freeman JC; Monif T; Kumar KS; Kumar S; Mudnaik R; Katikaneni P
    Int J Clin Pharmacol Ther; 2013 Nov; 51(11):895-907. PubMed ID: 23673291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: examination of current bioequivalence criteria.
    Shram MJ; Quinn AM; Chen N; Faulknor J; Luong D; Sellers EM; Endrenyi L
    Clin Ther; 2012 May; 34(5):1170-81. PubMed ID: 22512898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologically Based Pharmacokinetic and Absorption Modeling for Osmotic Pump Products.
    Ni Z; Talattof A; Fan J; Tsakalozou E; Sharan S; Sun D; Wen H; Zhao L; Zhang X
    AAPS J; 2017 Jul; 19(4):1045-1053. PubMed ID: 28357656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and evaluation of novel barrier layer technologies for controlling venlafaxine hydrochloride release from tablet dosage form.
    Malewar N; Avachat M; Kulkarni S; Pokharkar V
    Pharm Dev Technol; 2015; 20(5):588-97. PubMed ID: 24754412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation, release and pharmacokinetics of a risperidone elementary osmotic pump system.
    Gong W; Liu Y; Mei DY; Yang M; Mei XG
    Drug Dev Ind Pharm; 2015 Mar; 41(3):464-9. PubMed ID: 24400982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug absorption from nifedipine hydrophilic matrix extended-release (ER) tablet-comparison with an osmotic pump tablet and effect of food.
    Abrahamsson B; Alpsten M; Bake B; Jonsson UE; Eriksson-Lepkowska M; Larsson A
    J Control Release; 1998 Mar; 52(3):301-10. PubMed ID: 9743450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of in-vivo pharmacokinetic profile for immediate and modified release oral dosage forms of furosemide using an in-vitro-in-silico-in-vivo approach.
    Otsuka K; Wagner C; Selen A; Dressman J
    J Pharm Pharmacol; 2015 May; 67(5):651-65. PubMed ID: 25644429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seizure Induced by a Therapeutic Dose of Venlafaxine ER: A Case Report.
    Ye C; Ninneman M; Christian JS; Zhang F; Musselman D
    J Psychiatr Pract; 2018 Mar; 24(2):117-120. PubMed ID: 29509182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.